4. (Amended) The pharmaceutical or veterinary paste formulation according to claim 1, comprising:

(a) a therapeutic agent selected from the group consisting of avermectins, milbemycins, nordulisporic acid and its derivatives, estrogens, progestins, androgens, substituted pyridyl methyl derivatives, phenylpyrazoles, COX-2 inhibitors and a proton pump inhibitor;

(b) fumed silica;

(c) a viscosity modifier comprised of two or more functional groups for forming hydrogen bonds on the surface of the fumed silica;

(d) an absorbent;

(e) a colorant; and

(f) a carrier selected from the group consisting of triacetin, a monoglyceride, a diglyceride, and a triglyceride.

C2

5. (Amended) The pharmaceutical or veterinary paste formulation according to claim 4, wherein the viscosity modifier is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene sorbiton monoleate, and poloxamers; the absorbent is selected from the group consisting of magnesium carbonate, calcium carbonate, starch, and cellulose and its derivatives; and the colorant is selected from the group consisting of titanium dioxide, dye and lake.

6. (Amended) The pharmaceutical or veterinary paste formulation according to claim 1, which, based upon total weight of composition, comprises:

(a) about 0.01 to about 50% of a therapeutic agent;

(b) about 0.02 to about 20% fumed silica;

(c) about 0.01% to about 20% of a viscosity modifier comprised of two or more functional groups for forming hydrogen bonds on the surface of the fumed silica;

(d) 0% to about 30% of an absorbent;

(e) 0% to about 20% of a colorant; and

(f) a carrier.

7. (Amended) The pharmaceutical or veterinary paste formulation according to claim 4, which based upon total weight of the composition, comprises:

(a) about 0.01 to about 50% of a therapeutic agent;

(b) about 1% to about 6.5% fumed silica;

(c) about 0.05% to about 5% of a viscosity modifier comprised of two or more functional groups for forming hydrogen bonds on the surface of the fumed silica;

(d) about 1% to about 10% of an absorbent;

(e) 0.01% to about 10% of a colorant; and

(f) a carrier.

C2 cont

11. (Amended) The pharmaceutical or veterinary paste formulation according to claim 5, wherein the therapeutic agent is a COX-2 inhibitor.

12. (Amended) The pharmaceutical or veterinary paste formulation according to claim 11, wherein the COX-2 inhibitor is 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one or 3-(cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one or pharmaceutically acceptable salts or hydrates of these compounds.

C3

13. (Amended) The pharmaceutical or veterinary paste formulation according to claim 12, wherein the COX-2 inhibitor is the polymorphic B form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl-5,5-dimethyl]-5H-furan-2-one.

Kindly add new claims 47-49, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents to read as follows:

-- 47. (New) The pharmaceutical or veterinary paste formulation according to claim 1, further comprising an absorbent.

48. (New) The pharmaceutical or veterinary paste formulation according to claim 1, further comprising a compound selected from the group consisting of a colorant, a stabilizer, a surfactant and a preservative.

49. (New) A pharmaceutical or veterinary paste formulation, which, based upon total weight of composition, comprises:

(a) 1.87% Ivermectin;

(b) 80.98% Corn oil;

(c) 7.65% Polysorbate 80;

(d) 2.0% Apple flavoring; and

(e) 7.5% Colloidal silicon dioxide; - -